Fiche publication
Date publication
mars 2020
Journal
Transplantation
Auteurs
Membres identifiés du Cancéropôle Est :
Dr ESCHWEGE Pascal
,
Pr HUBERT Jacques
Tous les auteurs :
Masset C, Boucquemont J, Garandeau C, Buron F, Morelon E, Girerd S, Ladrière M, Mourad G, Garrigue V, Cassuto E, Albano L, Foucher Y, Dantal J, Badet L, Brunet M, Buron F, Cahen R, Daoud S, Fournie C, Grégoire A, Koenig A, Lévi C, Morelon E, Pouteil-Noble C, Rimmelé T, Thaunat O, Delmas S, Garrigue V, Le Quintrec M, Pernin V, Serre JE, Eschwege P, Frimat L, Girerd S, Hubert J, Ladriere M, Laurain E, Leblanc L, Lecoanet P, Lemelle JL, Blancho G, Branchereau J, Cantarovich D, Chapelet A, Dantal J, Deltombe C, Figueres L, Garandeau C, Giral M, Gourraud-Vercel C, Hourmant M, Karam G, Kerleau C, Meurette A, Ville S, Kandell C, Moreau A, Renaudin K, Cesbron A, Delbos F, Walencik A, Devis A, Albano L, Cassuto E, ,,,,,
Lien Pubmed
Résumé
In nonimmunized patients, similar rejection rates are observed for patients who have undergone thymoglobulin (antithymocyte globulins [ATG]) or basiliximab (BSX) therapy. While ATG may improve delayed graft function, it may also be associated with higher infection rates and malignancy risk. We compared survival and clinical outcomes in elderly recipients with low immunological risk according to their induction therapy.
Référence
Transplantation. 2020 Mar;104(3):613-622
